These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1559790)

  • 1. Polyneuritis after HD Ara-C therapy for malignant lymphoma.
    Montalbetti L; Brambilla Pisoni G; Trotti G; Calloni MV
    Ital J Neurol Sci; 1992 Feb; 13(1):85. PubMed ID: 1559790
    [No Abstract]   [Full Text] [Related]  

  • 2. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cytosine arabinoside in non-Hodgkin's lymphoma.
    Kantarjian H; Barlogie B; Plunkett W; Velasquez W; McLaughlin P; Riggs S; Cabanillas F
    J Clin Oncol; 1983 Nov; 1(11):689-94. PubMed ID: 6366130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose cytosine arabinoside-associated pancreatitis.
    Siemers RF; Friedenberg WR; Norfleet RG
    Cancer; 1985 Oct; 56(8):1940-2. PubMed ID: 2411382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI; Weinberg KI; Sato JK; Lenarsky C; Willoughby ML; Coates TD; Ozkaynak MF; Parkman R
    Cancer Res; 1989 Jan; 49(1):241-7. PubMed ID: 2908850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
    Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
    Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
    Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
    Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new modified prophylactic scheme against liposomal cytarabine-induced arachnoiditis in adult patients with lymphoma.
    Sanchez-Gonzalez B; Llorente A; Sancho JM; Panizo C; Guinea JM; Cladera A; Mateos C; Salar A
    Leuk Lymphoma; 2013 Apr; 54(4):892-3. PubMed ID: 22988933
    [No Abstract]   [Full Text] [Related]  

  • 9. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage therapy with methyl-gag, high-dose Ara-C, M-Amsa, and ifosfamide (MAMI) for recurrent or refractory lymphoma.
    Hayat M; Ostronoff M; Gilles E; Zambon E; Baume D; Moran A; Carde P; Droz JP; Pico JL
    Cancer Invest; 1990; 8(1):1-5. PubMed ID: 2350713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy in the management of intraocular lymphoma.
    Strauchen JA; Dalton J; Friedman AH
    Cancer; 1989 May; 63(10):1918-21. PubMed ID: 2702565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of intraocular lymphoma with high-dose Ara-C.
    Baumann MA; Ritch PS; Hande KR; Williams GA; Topping TM; Anderson T
    Cancer; 1986 Apr; 57(7):1273-5. PubMed ID: 2418934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ARA-C).
    Breithaupt H; Pralle H; Eckhardt T; von Hattingberg M; Schick J; Löffler H
    Cancer; 1982 Oct; 50(7):1248-57. PubMed ID: 7104969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
    Morra E; Lazzarino M; Inverardi D; Brusamolino E; Orlandi E; Canevari A; Pagnucco G; Bernasconi C
    J Clin Oncol; 1986 Aug; 4(8):1207-11. PubMed ID: 3461134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial.
    Wu J; Duan L; Zhang L; Sun Z; Fu X; Li X; Li L; Wang X; Zhang X; Li Z; Yu H; Chang Y; Nan F; Yan J; Tian L; Wang X; Zhang M
    J Neurooncol; 2018 Nov; 140(2):427-434. PubMed ID: 30109672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral neuropathy associated with high-dose Ara-C therapy.
    Borgeat A; De Muralt B; Stalder M
    Cancer; 1986 Aug; 58(4):852-4. PubMed ID: 3013396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cytosine arabinoside (Ara-C) syndrome.
    Castleberry RP; Crist WM; Holbrook T; Malluh A; Gaddy D
    Med Pediatr Oncol; 1981; 9(3):257-64. PubMed ID: 6941069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excessive spinal cord toxicity from intensive central nervous system-directed therapies.
    Watterson J; Toogood I; Nieder M; Morse M; Frierdich S; Lee Y; Moertel CL; Priest JR
    Cancer; 1994 Dec; 74(11):3034-41. PubMed ID: 7954266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside.
    DeAngelis LM; Kreis W; Chan K; Dantis E; Akerman S
    Cancer Chemother Pharmacol; 1992; 29(3):173-7. PubMed ID: 1733548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.